Vascular Conference Program

SR. NO. Day 1 – Sunday, November 17 Day 2 – Monday, November 18 Day 3 – Tuesday, November 19
1 IPF SESSION I
Chairs: Alberto Caggiati, Antonios Gasparis
IPF SESSION II
Chair: Ashkan Haghshenas, Malay Patel
SCIENTIFIC SESSION:
Complications and failures in phlebological treatment Chair: Alun H Davies
2 Dr. Graciela Figueiredo
8.00-8.10
Presidential Lecture
Dr. Enrico Cappello, Dr. Grzegorz Halena
IPF Consensus Report – Contraindications to Sclerotherapy
Dr. Victor Canata
Underuse, overuse or misuse of the phlebological treatment? – treatment overuse or insufficiently trained operators
3 Dr. Oscar Bottini
8.10-8.20
IPF Future: Our Vision and Mission
Dr. Tobias Hirsch, Dr. Mabel Bussati
IPF Consensus Report – Pelvic Venous Insufficiency
Dr. Steve Elias
Matting is the issue – how to avoid and treat?
4 Dr. Marianne de Maeseneer
8.20 – 8.30
IPF Scientific Committee. Major Scientific Findings in Phlebology in the Past 2 Years
Dr. Louay Altarazi, Dr. Jawed Fareed
IPF Consensus Report – Venous Mapping
Hyperpigmentation after vein treatment
Eberhard Rabe
Dermatologists point of view
5 Dr. Guillermo Camicia
8.30 – 8.40
Post-thrombotic Syndrome: Need for a New Instrument
Dr. Niels Bækgaard
IPF Consensus Report – Venous Rehabilitation
Hyperpigmentation after vein treatment
Dr. Larisa Chernukha
Phlebologists point of view
6 Dr. Kathleen Gibson
8.40 – 8.45
IPF Operations: Need for Reform
Dr. Denis Borsuk, Dr. Alun H Davies
Pan-American Consensus on Ultrasound-guided Foam Sclerotherapy
Dr. Malay Patel
Visual and Neurological complications of sclerotherapy
7 Dr. Devendra B Dekiwadia
8.45 – 8.55
IPF Education Program: Our exciting new initiatives
IPF Bauerfeind Award Presentation
Dr. Grzegorz Halena, Dr. Steve Elias
Influence of compression treatment in patients with Pelvic Congestion Syndrome
Dr. Rodrigo Bono Fukushima
EHIT and ostial thrombotic complications after saphenous ablation – do we need routinely follow up the patients with US?
8 Dr. Oscar Bottini
8.55 – 9.00
IPF Educational Modules
IPF Servier Award Presentation
Dr. Tobias Hirsch
The Athlete’s Vein: Venous Adaptations of the Lower Limb in Endurance Athletes
Alessandro Frullini
A multicentric study on the role of heparin prophylaxis of thrombotic complications in foam sclerotherapy (the Prosclep study)
9 IPF Vice Presidents: Dr. Denis Borsuk, Dr. Devendra B Dekiwadia, Dr Malay Patel, Dr. Ravul Jindal
9.00 – 9.20
Around the Globe with IPF: North America, Latin America, Northern Europe, Near East, North Africa, Southern Europe, Asia and Oceania
IPF Kreussler Award Presentation
Dr. Alberto Caggiati
Reducing Hyperpigmentation After Sclerotherapy using an antithrombotic drug: (RHyAS) trial Midterm results
Frantisek Zernovicky
NTNT ablation complications can happen – how to deal with it?
10 Discussion
9.20 – 9.30
Discussion Dr. Antonios Gasparis
Granuloma formtion as a long term complication of glue
11 KEYNOTE LECTURE: Mark Meissner
9.35 – 09.55
Chronic pelvic vein disease 2019 update: what do we know? what we do not know?
KEYNOTE LECTURE: Alfred Obermayer
From understanding chronic venous ulceration to effective treatment
Discussion
12 Coffee break
10.00 – 10.30
Coffee break Coffee break
13 SCIENTIFIC SESSION:
Foam Sclerotherapy – from the consensus document to the clinical practice
10.30 – 12.00
Chair: Dr. Ravul Jindal
SCIENTIFIC SESSION:
Post-thrombotic syndrome – towards consensus on definition, scoring and effective preventionChair: M. MeissnerCo-moderators: Dr. Jawed Fareed, Dr. Victor Canata
SCIENTIFIC SESSION:
Focus on varicose vein recurrenceChair: M. de MaeseneerCo-moderators: M. Meissner, A. Mumme, F. Pannier, U. Maurins, Dong-ik Kim, T. Urbanek
14 Dr. Tobias Hirsch
10.30 – 10.40
New European Guidelines on Sclerotherapy – what is new?
Mark Meissner
What is post-thrombotic syndrome and how we measure this?
Marlin Schul
Does the choice of the treatment method decrease the recurrence rate?
15 Alberto Caggiati
10.40 – 10.55
Tips and tricks of successfully maintaining and injecting foam – what should we know about US guided foam sclerotherapy?
Alun H Davies
Secondary chronic venous disease – the role of reflux and obstruction
Antonios Gasparis
Standard for the investigation of the saphenous terminal and preterminal valve on duplex
16 Ashkan Haghshenas
10.55 – 11.05
Foam sclerotherapy – the safety issue
Dr Denis Borsuk
Management of the post-thrombotic syndrome – lessons learned
Dr Devendra B Dekiwadia
Alarmingly high rates of groin recurrence following endovenous laser therapy
17 Dr Malay Patel
11.05 – 11.15
Saphenous vein sclerotherapy – does tumescence and blood irrigation make the difference?
Dr. Luiz Fernando Albernaz
PTS predictive factors – what do we know about?
Dr. Ravul Jindal​
Reflux sources after surgical treatment and endovenous ablation: does accessory saphenous, big tributaries and perforator closure really work in the varicose vein recurrence prevention?
18 Enrico Cappello
11.15 – 11.25
Foam Sclerotherapy in C1 treatment
Graciela Figueiredo
Does the compression and early mobilization work in PTS prevention?
Grzegorz Halena
Primary saphenous stump closure – lessons learned from “0 level“ saphenous ostial ablation
19 Guillermo Camicia
11.25 – 11.35
How sclerothepary can replace phlebectomy in primary therapeutic attempt or in the recurrent varicose vein treatment?
Jawed Fareed
Does thrombolysis work in PTS prevention? – recent RC trial results: Attract trial data
Kathleen Gibson
What do we need: better technology or better strategy? Varicose veins after saphenous ablation and surgery: disease recurrence or disease progression?
20 Larisa Chernukha
11.35 – 11.45
Is atrophie blanche irreversible? Effects of foam sclerotherapy
Louay Altarazi
The Effect of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome – CAVA trial subgroup analysis
Mabel Bussati
Varicose vein surgery in postthrombotic limb
21 Marianne de Maeseneer
11.45 – 11.55
Foam sclerotherapy – lessons from physics and chemistry
Niels Bækgaard
Does anticoagulation works in PTS prevention?
Oscar Bottini
Long term (20 years) results of preventive and venopreserving operations
22 Session summary: Rodrigo Bono Fukushima
11.55 – 12.00
Discussion will continue during the LUNCH with the Sclerotherapy Experts – Multi Hall S4 12.00-12.45
Discussion: PTS definition, criteria and assessment have to be updated Session summary
Discussion will continue during the LUNCH with the Experts – Multi Hall S4 12.05-13.00
23 Lunch
12.00 – 13.00
Lunch
Discussion with PTS Experts – Exhibition Area/Discussion Corner 12.00-12.40
Discussion moderator: M. Meissner
Experts: P. Prandoni, A. Davies, N. Baekgaard, A. Gasparis, S. Black, M. Lichtenberg, S. Gianesini, T. Urbanek, C. Wittens, Z. Krasiński, N. Labropoulos, M. de Maessener, H. Bjarnason, S. Elias, L. Kabnick, T. Hirsch, E. Shaydakov, Z. Lazarashvili
Lunch
24 SCIENTIFIC SESSION:
C0s – towards consensus on the diagnostics and therapy
13.00 – 14.15
Chair: A. NicolaidesCo-moderators: E. Rabe, N. Labropoulos, C. Allegra, S. Kakkos, M. Schul , A. Jawień
SCIENTIFIC SESSION:
Truncal varicose veins – therapeutic opportunity updateChair: N. LabropoulosCo-moderators: N. Morrison, A. Mumme, U. Maurins, M. Schul, L. Moraglia, A. Zielinski
INDUSTRY SUPPORTED SESSION
Compression treatment in Phlebology and Lymphology: today and in the future
Session supported by MEDIChair: N. Morrison, E. Rabe
25 Steve Elias
13.00 – 13.10
Epidemiology of C0s – what do we know about?
Tobias Hirsch
Patient presentation and examination – truncal varicose veins
VS at UIP Krakow 2019
Victor Canata
Post-thrombotic syndrome: why do we need compression?
26 Alberto Caggiati
13.10 – 13.20
The link between hemodynamics and signs as well as symptoms of the chronic venous disease
Alun H Davies
Update of technology and results for thermal ablation
Antonios Gasparis
Adjustable velcro devices: the future gold-standard treatment in venous ulcer?
27 Ashkan Haghshenas
13.20 – 13.30
Symptoms of the chronic venous disease learning through a clinical casev. How to assess the symptoms of the chronic venous disease – 2019 update?
Dr Denis Borsuk
Update of technology and results for thermal ablation
Dr Devendra B Dekiwadia
Compression, well-being and PNEI (Psychoneuroendocrineimmunology)
28 Dr Malay Patel
13.30 – 13.40
Chronic venous disease progression – is it unavoidable?
Dr. Luiz Fernando Albernaz
Update of technology and results for non-thermal ablation
Dr. Ravul Jindal
Treating skin inflammation with compression
29 Enrico Cappello
13.40 – 13.50
C0s diagnostics – objective evaluation and possibilities of confirmation of the chronic disease presence in C0s patients
Graciela Figueiredo
Achim Mumme
Surgical stripping is still in the game!
Discussion
30 Grzegorz Halena
13.50 – 14.00
C0s treatment possibilities – 2019 update
Truncal varicose vein surgical treatment
Sergio Gianesini
Saphenous vein sparing surgery: when, how and how long does it last?
SCIENTIFIC SESSION:
Research from the world – awarded abstracts session (7 min presentations + 3 min discussions)Chair: K. Parsi, C. Allegra
31 Discussion
14.00 – 14.15
Guillermo Camicia
An overview of the RCT on the truncal VV treatment – do we know which method is best one?
Thodur Vasudevan, Ramon L. Varcoe, David A. Robinson, Andrew A. Hill, Andrew Holden, Odette Hart
Initial Results Of A First-In-Man Clinical Trial For Endovenous Deep Venous Valve Formation To Treat Chronic Venous Insufficiency
32 SCIENTIFIC SESSION:
Innovations in phlebology
14.15 – 15.30
Chair: S. EliasCo-moderators: R. Milleret, Ch. Ragg, W. Chi, T. Yamaki, E. Shaydakov, G. Halena
The problems in truncal varicose vein treatment
Marlin Schul
Options for large diameter saphenous vein
Huw Davies, Mike Watkins, Gareth Bate, Tracy Ellis, Andrew Bradbury
Neurological Events Following Ultrasound Guided Foam Sclerotherapy Using Sodium 5. Tetradecyl Sulphate (Fibrovein)
33 Jawed Fareed
14.15 – 14.25
Fully percutaneously created or surgically inserted artificial vein valves in CVD treatment – research status and first clinical data
Simultaneous or staged varicose vein treatment after saphenous ablation
Debate: Staged treatment brings benefits
Uldis Maurins
For the motion
Kathleen Gibson
Relationship Between Medical Compression And Intramuscular Pressure As An Explanation Of A Compression Paradox
34 Larisa Chernukha
14.25 – 14.35
Recent developments in the dedicated venous stents – lessons learned and future direction
Simultaneous or staged varicose vein treatment after saphenous ablation
Debate: Staged treatment brings benefits
Alun Davies
Against the motion
Louay Altarazi
Relationship Of Reflux Patterns To Health-Related Quality Of Life And Clinical Severity Scores
35 Mabel Bussati
14.35 – 14.45
Hyaluronan injection based treatment in phlebology – why and when?
Marianne de Maeseneer
“Choose wisely” – chemical or thermal ablation in the treatment of the incompetent saphenous vein (the French proposal)
Niels Bækgaard
Egyptian Experience In Venous Ulcer Abolishing Most Distal Reflux: Does It Count?
36 Oscar Bottini
14.45 – 14.55
First percutaneous – non invasive – vein ablations using high intensity focused ultrasound (HIFU)
Rodrigo Bono Fukushima
What the new German guidelines on varicose vein treatment say?
Session Summary: Steve Elias
37 Tobias Hirsch
14.55 – 15.05
Transcutaneous obliteration of varicose veins by ultrasound: HIFU and Cavitation solutions
Victor Canata
Does the choice of the method really matters for truncal varicose veins treatment?
Coffee break
38 Alberto Caggiati
15.05 – 15.15
Telemetric vein diagnostics: how does technology enable patients compliance?
Alun H Davies
Superficial chronic venous disease: from HOW to WHAT and WHY to treat
SCIENTIFIC SESSION:
C1 Treatment updateChair: A. Cavezzi
39 Antonios Gasparis
15.15 – 15.25
SFALT: Sclerofoam assisted laser therapy for saphenous refluxes: an innovative tumescence-free technique
Jaroslav Strejček, Michael Schubert
Endovenous laser ablation with 1940 nm, new direction or blind street?
Ashkan Haghshenas
C1 pathology or another disease – be careful!
40 Session summary: Dr Denis Borsuk
15.25 – 15.30
Discussion with the Innovators – Exhibition Area/Discussion Corner
Discussion Dr Devendra B Dekiwadia
How to optimize the small vein chemical ablation – liquid or foam ?!
41 Coffee break
15.30 – 16.00
Coffee break Dr Malay Patel
C1 sclerotherapy – state of art
42 SCIENTIFIC SESSION:
What is new in our understanding of the chronic venous disease
16.00 – 17.35
Chair: A. NicolaidesCo-moderators: N. Morrison, C. Allegra, P. Thibault, Ch. Lattimer, T. Zubilewcz, S. Kakkos
SCIENTIFIC SESSION:
Great Venous Leg Ulcer Forum – conservative or aggressive approach in post – EVRA eraChair: D. HeimCo-moderators: G. Mosti, A. Davies, G M. Malouf, A. Obermayer, W. Taha, A. Jawień
Dr. Luiz Fernando Albernaz
Compression following sclerotherapy of C1 varicose veins – necessary or not? Results of the SklerKomp Study
43 Dr. Ravul Jindal
16.00 – 16.10
Our current understanding of the chronic venous obstruction
Enrico Cappello
Venous leg ulcer treatment – do we really have consensus? /summary of the existing guidelines/
Graciela Figueiredo
Virtual reality sclerotherapy – the tool for better results
44 Grzegorz Halena
16.10 – 16.20
Chronic venous thrombosis – does it really exsist
Guillermo Camicia
Global management of the venous leg ulcer in the pre EVRA era
Jawed Fareed
CLaCS (Cryo-Laser and Cryo-Sclerotherapy) in C1 Patients
IMAP at UIP Krakow 2019
45 Kathleen Gibson
16.20 – 16.30
What is new in our understanding of the cerebral venous outflow? – possible link with neurodegeneration
Larisa Chernukha
No ulcer treatment without hemodynamic analysis!
Louay Altarazi
SCORE 9-1: instructions for users and clinical application
IMAP at UIP Krakow 2019
46 Mabel Bussati
16.30 – 16.40
Neck vein obstruction: Diagnosis and the role of chronic Chlamydophila pneumoniae infection
Marianne de Maeseneer
Which compression in the venous leg ulcer patients? – practical advices
Niels Bækgaard
Transdermal laser for varicose veins from physics to practice
47 Oscar Bottini
16.40 – 16.50
Every valve tells a story! what do we know from HR Ultrasound research on the valve impact on the CVD occurrence and progression – clinical implications
Rodrigo Bono Fukushima
Venous leg ulcer treatment – does pharmacotherapy matter?
Steve Elias
Best standards in the use of transdermal laser in the treatment of the reticular veins and telangiectasias
48 Tobias Hirsch
16.50 – 17.00
Venous diameter, clinical severity and quality of life – does the size of the incompetent vein matters?
Dr Ravul Jindal
EVRA trial – early invasive reflux ablation brings benefits to the VLU leg ulcer patients
Dr Ravul Jindal
What is new in the transcutaneous laser treatment of the C1 pathology and complication treatment
49 Alun H Davies
17.00 – 17.10
What is new in our understanding of the chronic venous disease pathogenesis at the cell and tissue level
Antonios Gasparis
Venous Disease, Ulcer Pathophysiology and Novel Treatments
Ashkan Haghshenas
Association between transdermal laser and polidocanol foam. Advantages and disadvantages
50 Dr Denis Borsuk
17.10 – 17.20
Obesity and Inflammation in venous and lymphatic diseases
Dr Devendra B Dekiwadia
The role of the reflux sourcing and ablation in the venous leg ulcer treatment
Discussion
51 Dr Malay Patel
17.20 – 17.25
Guidelines from the world: 5 minutes for 5 emergent recommendations
Dr. Luiz Fernando Albernaz
Aggressive local venous leg ulcer treatment – does it help?
52 Discussion
17.25 – 17.35
Session Summary: Dr. Ravul Jindal
Enrico Cappello
Combined and simultaneous reflux ablation and local surgical treatment – lessons learned
53 Graciela Figueiredo
Update of the negative wound pressure therapy for the venous leg ulcer
54 Grzegorz Halena
Venous leg ulcer treatment based on the chronic venous disease pathophysiology – lessons learned
55 Guillermo Camicia
1 year outcomes of Venaseal Glue ablation in diabetics with Venous leg ulcer
56 Jawed Fareed
Topical Sevoflurane As A New Treatment Modality For Painful Venous Leg Ulcers
57 Discussion
58 Discussion
17.25 – 17.35
Session Summary: Kathleen Gibson
Larisa Chernukha
Combined and simultaneous reflux ablation and local surgical treatment – lessons learned
59 Discussion
17.25 – 17.35
Session Summary: Louay Altarazi
Mabel Bussati
Combined and simultaneous reflux ablation and local surgical treatment – lessons learned